Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 2158-2164

  Du, Yunpeng ^a   Tang, Jie ^a   Li, Guanyuan ^a,b   Berti Mattera, Liliana ^a,c   Lee, Chieh Allen ^d   Bartkowski, Darian ^d   Gale, David ^d   Monahan, Joe ^d   Niesman, Michael R ^d   Alton, Gordon ^d   Kern, Timothy S ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CYCLOOXYGENASE 2; GLYCOSYLATED HEMOGLOBIN; HEAT SHOCK PROTEIN 27; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NITRIC OXIDE; PHA 666859; PROTEIN BAD; SUPEROXIDE; THREONINE; TYROSINE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PTGS2 PROTEIN, RAT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE CONTROL; DISEASE DURATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HYPERGLYCEMIA; IC 50; LEUKOSTASIS; LOW DRUG DOSE; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY NERVE; TREATMENT DURATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; HYPERALGESIA; LEWIS RAT; METABOLISM; PATHOLOGY; PERICYTE; RETINA BLOOD VESSEL; SENSORY RECEPTOR; TOUCH; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HYPERALGESIA; LEUKOSTASIS; MALE; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERICYTES; PYRAZOLES; PYRIMIDINES; RATS; RATS, INBRED LEW; RETINAL VESSELS; SENSORY RECEPTOR CELLS; SUPEROXIDES; TOUCH;

EID: 77951214647     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3674     Document Type: Article

References (54)

1. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
2. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30: 65-84.
3. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18: 1450-1452.
4. Badger AM, Roshak AK, Cook MN, et al. Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage. 2000;8:434-443.
5. Guan Z, Buckman SY, Pentland AP, Templeton DJ, Morrison AR. Induction of cyclooxygenase-2 by the activated MEKK13SEK1/ MKK43p38 mitogen-activated protein kinase pathway. J Biol Chem. 1998;273:12901-12908.
6. Guan Z, Buckman SY, Springer LD, Morrison AR. Regulation of cyclooxygenase-2 by the activated p38 MAPK signaling pathway. Adv Exp Med Biol. 1999;469:9-15.
7. Saccani S, Pantano S, Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol. 2002;3:69-75.
8. Nick JA, Young SK, Brown KK, et al. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol. 2000;164:2151-2159.
9. Haddad EB, Birrell M, McCluskie K, et al. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol. 2001;132:1715-1724.
10. Kim JK, Pedram A, Razandi M, Levin ER. Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. J Biol Chem. 2006;281:6760-6767.
11. Perregaux DG, Dean D, Cronan M, Connelly P, Gabel CA. Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Mol Pharmacol. 1995;48:433-442.
12. Johnson GV, Bailey CD. The p38 MAP kinase signaling pathway in Alzheimer's disease. Exp Neurol. 2003;183:263-268.
13. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kappaBsignaling suppresses inflammatory bowel disease. FASEB J. 2004; 18:1550-1552.
14. Roth S, Shaikh AR, Hennelly MM, Li Q, Bindokas V, Graham CE. Mitogen-activated protein kinases and retinal ischemia. Invest Ophthalmol Vis Sci. 2003;44:5383-5395.
15. Otto M, Bak S, Bach FW, Jensen TS, Sindrup SH. Pain phenomena and possible mechanisms in patients with painful polyneuropathy. Pain. 2003;101:187-192.
16. Burnette BL, Selness S, Devraj R, et al. SD0006: a potent, selective and orally available inhibitor of p38 kinase. Pharmacology. 2009; 84:42-60.
17. Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med. 2003; 35:1491-1499.
18. Du Y, Sarthy V, Kern T. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol. 2004;287:R735-R741.
19. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007;56:337-345.
20. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438-440.
21. Zheng L, Szabo C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes. 2004;53:2960-2967.
22. Kern TS, Tang J, Mizutani M, et al. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci. 2000;41:3972-3978.
23. Kern TS, Engerman RL. Pharmacologic inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001;50: 1636-16342.
24. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain. 1996;68: 293-299.
25. Berti-Mattera LN, Kern TS, Siegel RE, Nemet I, Mitchell R. Sulfasalazine blocks the development of tactile allodynia in experimentally diabetic rats. Diabetes. 2008;57(10):2801-2808.
26. Rousseau S, Dolado I, Beardmore V, et al. CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway. Cell Signal. 2006;18:1897-1905.
27. Mikkelsen SS, Jensen SB, Chiliveru S, et al. RIG-I-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells: dependence on TRAF2 and TAK1. J Biol Chem. 2009;284:10774-10782.
28. Sullivan JE, Holdgate GA, Campbell D, et al. Prevention of MKK6- dependent activation by binding to p38alpha MAP kinase. Biochemistry. 2005;44:16475-16490.
29. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807-869.
30. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004;4:372-377.
31. Lal AS, Clifton AD, Rouse J, Segal AW, Cohen P. Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. Biochem Biophys Res Commun. 1999; 259:465-470.
32. Bao W, Behm DJ, Nerurkar SS, et al. Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol. 2007;49: 362-368.
33. Yoo BK, Choi JW, Shin CY, et al. Activation of p38 MAPK induced peroxynitrite generation in LPS plus IFN-gamma-stimulated rat primary astrocytes via activation of iNOS and NADPH oxidase. Neurochem Int. 2008;52:1188-1197.
34. Igarashi M, Wakasaki H, Takahara N, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest. 1999;103:185-195.
35. Adhikary L, Chow F, Nikolic-Paterson DJ, et al. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia. 2004;47:1210-1222.
36. Chen H, Brahmbhatt S, Gupta A, Sharma AC. Duration of streptozotocin- induced diabetes differentially affects p38-mitogen-activated protein kinase (MAPK) phosphorylation in renal and vascular dysfunction. Cardiovasc Diabetol. 2005;4:3.
37. Komers R, Lindsley JN, Oyama TT, Cohen DM, Anderson S. Renal p38 MAP kinase activity in experimental diabetes. Lab Invest. 2007;87:548-558.
38. Igarashi M, Hirata A, Yamaguchi H, et al. Characterization of activation of MAP kinase superfamily in vasculature from diabetic rats. J Atheroscler Thromb. 2007;14:235-244.
39. Agthong S, Tomlinson DR. Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy. Ann N Y Acad Sci. 2002;973:359-362.
40. Macfarlane WM, Smith SB, James RF, et al. The p38/reactivating kinase mitogen-activated protein kinase cascade mediates the activation of the transcription factor insulin upstream factor 1 and insulin gene transcription by high glucose in pancreatic beta-cells. J Biol Chem. 1997;272:20936-20944.
41. Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int. 2001;60:858-871.
42. Soloaga A, Thomson S, Wiggin GR, et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 2003;22:2788-2797.
43. Chen C, Chen YH, Lin WW. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology. 1999;97:124-129.
44. Yuan Z, Feng W, Hong J, Zheng Q, Shuai J, Ge Y. p38MAPK and ERK promote nitric oxide production in cultured human retinal pigmented epithelial cells induced by high concentration glucose. Nitric Oxide. 2009;20:9-15.
45. Parinandi NL, Kleinberg MA, Usatyuk PV, et al. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L26-L38.
46. Yamamori T, Inanami O, Nagahata H, Cui Y, Kuwabara M. Roles of p38 MAPK, PKC and PI3-K in the signaling pathways of NADPH oxidase activation and phagocytosis in bovine polymorphonuclear leukocytes. FEBS Lett. 2000;467:253-258.
47. Wong JW, Shi B, Farboud B, et al. Ultraviolet B-mediated phosphorylation of the small heat shock protein HSP27 in human keratinocytes. J Invest Dermatol. 2000;115:427-434.
48. Garmyn M, Mammone T, Pupe A, Gan D, Declercq L, Maes D. Human keratinocytes respond to osmotic stress by p38 map kinase regulated induction of HSP70 and HSP27. J Invest Dermatol. 2001;117:1290-1295.
49. Rogalla T, Ehrnsperger M, Preville X, et al. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem. 1999;274:18947-18956.
50. Chen XQ, Fung YW, Yu AC. Association of 14-3-3gamma and phosphorylated bad attenuates injury in ischemic astrocytes. J Cereb Blood Flow Metab. 2005;25:338-347.
51. Calcutt NA. Experimental models of painful diabetic neuropathy. J Neurol Sci. 2004;220:137-139.
52. Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003;23:4017-4022.
53. Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23:2517-2521.
54. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol. 2003;521:1-21.